Neurodegenerative disease assay kit MemoryLinc®

bloodplasmacerebrospinal fluid

NDs are multifactorial complex disorders with genetics playing a crucial role in their development. The challenge of their early detection and precise diagnosis is ever more pressing. Traditional diagnostic methods are often invasive, such as cerebrospinal fluid (CSF) sampling, or costly, such as PET scans. Thus, the demand for a less invasive, blood-based test that can accurately diagnose NDs early, aid in drug development, and inform treatment choices is significant Features and benefits FIRST IN CLASS TEST for the measurement of microRNAs in peripheral blood & plasma. NCRNA BIOMARKERS for the diagnostic of MCI, early Alzheimer's and other dementia types INVESTIGATION OF A NOVEL CLASS of therapeutic targets. DIRECT INSIGHT OF BRAIN CONDITION using blood without needing brain biopsies Simplified workflow Sample Preparation RNA Extraction RT-QPCR Data Analysis OPTIMIZE YOUR BIOMARKER PROJECTS AND DEVELOPMENT PROGRAMS From concept to regulatory qualification, with significant experience in each step, we provide steadfast support across diverse areas Design of biomarker program and analytical development Planning and study design Development of SOPs Standard Operating Procedures Regulatory support preparing dossiers and opinion meeting Biomarker regulatory qualification for IVD development